Is ABEONA THERAPEUTICS INC. (ABEO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.8% / 30% | 37.2% / 30% | 0.6% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 8.8% / 33% | 37.2% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 21.2% / 33% | 89.7% / 33% | 1.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 8.8% / 33% | 37.2% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 21.2% / 33% | 89.7% / 33% | 1.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -422.7% | |
| Net Margin | 1223.1% | |
| Return on Equity (ROE) | 70.0% | |
| Return on Assets (ROA) | -34.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$56M |
| Free Cash Flow | -$58M |
| Total Debt | $23M |
| Debt-to-Equity | 15.7 |
| Current Ratio | 6.9 |
| Total Assets | $109M |
Price & Trading
| Last Close | $4.33 |
| 50-Day MA | $4.99 |
| 200-Day MA | $5.51 |
| Avg Volume | 1.2M |
| Beta | 1.2 |
|
52-Week Range
$3.93
| |
About ABEONA THERAPEUTICS INC. (ABEO)
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ABEONA THERAPEUTICS INC. (ABEO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ABEONA THERAPEUTICS INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ABEONA THERAPEUTICS INC.'s debt ratio?
ABEONA THERAPEUTICS INC.'s debt ratio is 8.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 21.2%.
What are ABEONA THERAPEUTICS INC.'s key financial metrics?
ABEONA THERAPEUTICS INC. has a market capitalization of $245M, trailing P/E ratio of 4.2. Return on equity stands at 70.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.